Evidence map›Paper›PMID 36276846›Full record

ReviewEvidence-based complementary and alternative medicine : eCAM2022

Correlation of Glucose Metabolism with Cancer and Intervention with Traditional Chinese Medicine.

Gui-Hua Lai, Fei Wang, Duo-Rui Nie, Shu-Jun Lei, Zhuo-Jun Wu, Jian-Xiong Cao, Lan-Lan Tang

Abstract readReview
In one paragraph

Review in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gui-Hua LaiGraduate School, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.ORCID https://orcid.org/0000-0002-5820-9355
Fei WangGraduate School, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.ORCID https://orcid.org/0000-0002-5580-6138
Duo-Rui NieGraduate School, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.ORCID https://orcid.org/0000-0003-3412-1196
Shu-Jun LeiGraduate School, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.ORCID https://orcid.org/0000-0002-3110-983X
Zhuo-Jun WuGraduate School, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.
Jian-Xiong CaoSchool of Continuing Education, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.ORCID https://orcid.org/0000-0003-1501-1565
Lan-Lan TangNingxiang Hospital of Chinese Medicine, Ningxiang, Hunan 410399, China.ORCID https://orcid.org/0000-0002-3180-3258

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a complex disease with several distinct characteristics, referred to as "cancer markers" one of which is metabolic reprogramming, which is a common feature that drives cancer progression. Over the last ten years, researchers have focused on the reprogramming of glucose metabolism in cancer. In cancer, the oxidative phosphorylation metabolic pathway is converted into the glycolytic pathway in order to meet the growth requirements of cancer cells, thereby creating a microenvironment that promotes cancer progression. The precise mechanism of glucose metabolism in cancer cells is still unknown, but it is thought to involve the aberrant levels of metabolic enzymes, the influence of the tumor microenvironment (TME), and the activation of tumor-promoting signaling pathways. It is suggested that glucose metabolism is strongly linked to cancer progression because it provides energy to cancer cells and interferes with antitumor drug pharmacodynamics. Therefore, it is critical to unravel the mechanism of glucose metabolism in tumors in order to gain a better understanding of tumorigenesis and to lay the groundwork for future research into the identification of novel diagnostic markers and therapeutic targets for cancer treatment. Traditional Chinese Medicine (TCM) has the characteristics of multiple targets, multiple components, and less toxic side effects and has unique advantages in tumor treatment. In recent years, researchers have found that a variety of Chinese medicine monomers and compound recipes play an antitumor role by interfering with the reprogramming of tumor metabolism. The underlying mechanisms of metabolism reprogramming of tumor cells and the role of TCM in regulating glucose metabolism are reviewed in this study, so as to provide a new idea for antitumor research in Chinese medicine.

Identifiers

PMID36276846
PMCPMC9586738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.